↓ Skip to main content

Cerebrospinal fluid amyloid-β 42/40 ratio in clinical setting of memory centers: a multicentric study

Overview of attention for article published in Alzheimer's Research & Therapy, June 2015
Altmetric Badge

About this Attention Score

  • In the top 25% of all research outputs scored by Altmetric
  • High Attention Score compared to outputs of the same age (86th percentile)

Mentioned by

news
1 news outlet
twitter
3 tweeters

Citations

dimensions_citation
68 Dimensions

Readers on

mendeley
72 Mendeley
You are seeing a free-to-access but limited selection of the activity Altmetric has collected about this research output. Click here to find out more.
Title
Cerebrospinal fluid amyloid-β 42/40 ratio in clinical setting of memory centers: a multicentric study
Published in
Alzheimer's Research & Therapy, June 2015
DOI 10.1186/s13195-015-0114-5
Pubmed ID
Authors

Julien Dumurgier, Susanna Schraen, Audrey Gabelle, Olivier Vercruysse, Stéphanie Bombois, Jean-Louis Laplanche, Katell Peoc’h, Bernard Sablonnière, Ksenia V Kastanenka, Constance Delaby, Florence Pasquier, Jacques Touchon, Jacques Hugon, Claire Paquet, Sylvain Lehmann

Abstract

The cerebrospinal fluid (CSF) biomarkers amyloid-β (Aβ), tau and phosphorylated tau (p-tau181) are now used for the diagnosis of Alzheimer's disease (AD). Aβ40 is the most abundant Aβ peptide isoform in the CSF, and the Aβ 42/40 ratio has been proposed to better reflect brain amyloid production. However, its additional value in the clinical setting remains uncertain. A total of 367 subjects with cognitive disorders who underwent a lumbar puncture were prospectively included at three French memory centers (Paris-North, Lille and Montpellier; the PLM Study). The frequency of positive, negative and indeterminate CSF profiles were assessed by various methods, and their adequacies with the diagnosis of clinicians were tested using net reclassification improvement (NRI) analyses. On the basis of local optimum cutoffs for Aβ42 and p-tau181, 22% of the explored patients had indeterminate CSF profiles. The systematic use of Aβ 42/40 ratio instead of Aβ42 levels alone decreased the number of indeterminate profiles (17%; P = 0.03), but it failed to improve the classification of subjects (NRI = -2.1%; P = 0.64). In contrast, the use of Aβ 42/40 ratio instead of Aβ42 levels alone in patients with a discrepancy between p-tau181 and Aβ42 led to a reduction by half of the number of indeterminate profiles (10%; P < 0.001) and was further in agreement with clinician diagnosis (NRI = 10.5%; P = 0.003). In patients with a discrepancy between CSF p-tau181 and CSF Aβ42, the assessment of Aβ 42/40 ratio led to a reliable biological conclusion in over 50% of cases that agreed with a clinician's diagnosis.

Twitter Demographics

The data shown below were collected from the profiles of 3 tweeters who shared this research output. Click here to find out more about how the information was compiled.

Mendeley readers

The data shown below were compiled from readership statistics for 72 Mendeley readers of this research output. Click here to see the associated Mendeley record.

Geographical breakdown

Country Count As %
Belgium 2 3%
Germany 1 1%
Unknown 69 96%

Demographic breakdown

Readers by professional status Count As %
Researcher 15 21%
Student > Ph. D. Student 15 21%
Student > Master 11 15%
Other 5 7%
Student > Doctoral Student 5 7%
Other 13 18%
Unknown 8 11%
Readers by discipline Count As %
Neuroscience 15 21%
Biochemistry, Genetics and Molecular Biology 11 15%
Medicine and Dentistry 11 15%
Agricultural and Biological Sciences 11 15%
Psychology 5 7%
Other 6 8%
Unknown 13 18%

Attention Score in Context

This research output has an Altmetric Attention Score of 11. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 25 June 2015.
All research outputs
#1,273,054
of 12,561,272 outputs
Outputs from Alzheimer's Research & Therapy
#229
of 539 outputs
Outputs of similar age
#31,073
of 233,809 outputs
Outputs of similar age from Alzheimer's Research & Therapy
#1
of 1 outputs
Altmetric has tracked 12,561,272 research outputs across all sources so far. Compared to these this one has done well and is in the 89th percentile: it's in the top 25% of all research outputs ever tracked by Altmetric.
So far Altmetric has tracked 539 research outputs from this source. They typically receive a lot more attention than average, with a mean Attention Score of 18.0. This one has gotten more attention than average, scoring higher than 56% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 233,809 tracked outputs that were published within six weeks on either side of this one in any source. This one has done well, scoring higher than 86% of its contemporaries.
We're also able to compare this research output to 1 others from the same source and published within six weeks on either side of this one. This one has scored higher than all of them